Does psilocybin alter the brain's response to food choice and reward?

Exclusion Criteria20

• Current or previously diagnosed psychiatric disorder (as determined by the SCID).
• Current or past history within the last 5 years of meeting DSM-5 criteria for alcohol or drug
• dependence (excluding caffeine and nicotine), as determined by clinical interview and use of screening measures.
• An immediate family member with a diagnosed psychotic disorder (Schizophrenia spectrum Disorder or Bipolar I or II Disorder).
• History of suicide attempts.
• Use of any hallucinogen or psychedelic (including psilocybin, MDMA, LSD, mescaline, DMT, and other similar hallucinogenic compounds) within the past 12 months.
• Taking a contraindicated medication (SSRIs, SNRIs, MAOIs) at the time of recruitment.
• Current use of any of the following potent metabolic inducers or inhibitors: Inducers - Rifamycin (rifampin, rifabutin, rifapentine), anticonvulsants (carbamazepine, phenytoin, phenobarbital), nevirapine, efavirenz, paclitaxol, St John's Wort; Inhibitors - all HIV protease inhibitors, itraconazole, ketoconazole, erythromycin, clarithromycin, troleandomycin.
• Known conditions putting participants at risk for hypercalcaemia, Cushing's syndrome, hypoglycaemia, syndrome of inappropriate antidiuretic hormone secretion, or carcinoid syndrome.
• People with a medical requirement that they receive any of the following drugs with low therapeutic index within 12 hours after receiving psilocybin: ergot alkaloids, pimozide, midazolam, triazolam, lovastatin, simvastatin, fentanyl.
• A diagnosis of epilepsy or previous seizures.
• A diagnosis of Hepatic dysfunction or Renal insufficiency
• Body weight < 48kg or >100kg.
• Taking long-acting opioid pain medications (e.g. oxycodone sustained-release, morphine sustained release -- which are usually taken at 12-hour intervals) unless the last dose occurred at least 6 hours before psilocybin administration; such medication will not be taken again until at least 6 hours after psilocybin administration.
• Cardiovascular conditions: uncontrolled hypertension, (Systolic >140 and diastolic >90) angina, a previous clinically significant ECG abnormality (e.g. atrial fibrillation, arrhythmia, prolongation of QT/QTc interval), TIA in the last 6 months, stroke or cerebrovascular disease, peripheral or pulmonary vascular disease (no active claudication).
• Medically significant condition rendering unsuitability for the study (e.g., diabetes, epilepsy, severe cardiovascular disease, hepatic or renal failure etc).
• Treatment in another clinical trial involving an investigational product.
• A positive pregnancy test at initial assessment or during the study.
• Are unable to give adequate informed consent.
• Allergy to gelatine or lactose.